{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T21:52:15Z","timestamp":1787003535009,"version":"build-2736575974"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,8,17]],"date-time":"2023-08-17T00:00:00Z","timestamp":1692230400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,8,17]],"date-time":"2023-08-17T00:00:00Z","timestamp":1692230400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>A renewed interest in the use of psychedelics for treating obsessive compulsive disorder (OCD) has emerged in the last 20 years. But pre-clinical and clinical evidence remain scarce, and little is known about the factor determining the magnitude and persistence of the therapeutic effect. We therefore designed a retrospective online survey to explore, in the general population using psychoactive drugs, their impact on OCD symptoms. We also assessed the attitude of the participants towards the substance in term of frequency of intakes. In a sample of 174 participants, classic psychedelics were reported as the only substances effective at reducing OCD symptoms. In classic psychedelics users, symptoms reduction was associated with the intensity of acute effects, itself correlated to the dose. Reports on the persistence of the therapeutic effect varied from weeks to months, but we could not find any predicting factor. Finally, the occurrence and frequency of subsequent intakes, which seemed to be limited in our sample, were predicted by the magnitude and persistence of the therapeutic effect, respectively. Our observations support the hypothesis of classic psychedelics efficacy in reducing OCD symptoms but a careful evaluation of the persistence of this effect is still needed.<\/jats:p>","DOI":"10.1038\/s41598-023-39812-0","type":"journal-article","created":{"date-parts":[[2023,8,17]],"date-time":"2023-08-17T05:02:38Z","timestamp":1692248558000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Improvement in OCD symptoms associated with serotoninergic psychedelics: a retrospective online survey"],"prefix":"10.1038","volume":"13","author":[{"given":"Anne","family":"Buot","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecile","family":"Pallares","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alina","family":"Oganesyan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Daur\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Val\u00e9rie","family":"Bonnelle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Burgui\u00e8re","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joao Flores Alves","family":"Dos Santos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karim","family":"N\u2019Diaye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Ljuslin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pauline","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Verroust","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Wyplosz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margot","family":"Morgi\u00e8ve","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luc","family":"Mallet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,8,17]]},"reference":[{"key":"39812_CR1","doi-asserted-by":"publisher","unstructured":"American Psychiatric Association. Diagnostic and statistical manual of mental disorders (5th ed., text rev.). (2022) doi:https:\/\/doi.org\/10.1176\/appi.books.9780890425787.","DOI":"10.1176\/appi.books.9780890425787"},{"key":"39812_CR2","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S0140-6736(09)60240-3","volume":"374","author":"JS Abramowitz","year":"2009","unstructured":"Abramowitz, J. S., Taylor, S. & McKay, D. Obsessive-compulsive disorder. Lancet 374, 491\u2013499 (2009).","journal-title":"Lancet"},{"key":"39812_CR3","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1001\/jama.2017.2200","volume":"317","author":"ME Hirschtritt","year":"2017","unstructured":"Hirschtritt, M. E., Bloch, M. H. & Mathews, C. A. Obsessive-compulsive disorder: Advances in diagnosis and treatment. JAMA 317, 1358\u20131367 (2017).","journal-title":"JAMA"},{"key":"39812_CR4","doi-asserted-by":"crossref","unstructured":"Swierkosz-Lenart, K. et al. Therapies for obsessive-compulsive disorder: Current state of the art and perspectives for approaching treatment-resistant patients. Front. Psychiat. 14, (2023).","DOI":"10.3389\/fpsyt.2023.1065812"},{"key":"39812_CR5","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1038\/s41591-022-01879-z","volume":"28","author":"V Visser-Vandewalle","year":"2022","unstructured":"Visser-Vandewalle, V. et al. Deep brain stimulation for obsessive\u2013compulsive disorder: a crisis of access. Nat. Med 28, 1529\u20131532 (2022).","journal-title":"Nat. Med"},{"key":"39812_CR6","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1111\/j.1600-0447.1977.tb00149.x","volume":"55","author":"E Brandrup","year":"1977","unstructured":"Brandrup, E. & Vanggaard, T. LSD treatment in a severe case of compulsive neurosis. Acta Psychiatr. Scand. 55, 127\u2013141 (1977).","journal-title":"Acta Psychiatr. Scand."},{"key":"39812_CR7","first-page":"1239","volume":"144","author":"HL Leonard","year":"1987","unstructured":"Leonard, H. L. & Rapoport, J. L. Relief of obsessive-compulsive symptoms by LSD and psilocin. Am. J. Psychiatry 144, 1239\u20131240 (1987).","journal-title":"Am. J. Psychiatry"},{"key":"39812_CR8","doi-asserted-by":"crossref","first-page":"111","DOI":"10.2466\/pr0.1964.14.1.111","volume":"14","author":"C Savage","year":"1964","unstructured":"Savage, C., Savage, E., Fadiman, J. & Harman, W. LSD: Therapeutic effects of the psychedelic experience. Psychol. Rep. 14, 111\u2013120 (1964).","journal-title":"Psychol. Rep."},{"key":"39812_CR9","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1097\/00004714-199604000-00011","volume":"16","author":"KR Hanes","year":"1996","unstructured":"Hanes, K. R. Serotonin, psilocybin, and body dysmorphic disorder: A case report. J. Clin. Psychopharmacol. 16, 188\u2013189 (1996).","journal-title":"J. Clin. Psychopharmacol."},{"key":"39812_CR10","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1080\/02791072.2020.1849879","volume":"53","author":"A Lugo-Radillo","year":"2021","unstructured":"Lugo-Radillo, A. & Cortes-Lopez, J. L. Long-term amelioration of OCD symptoms in a patient with chronic consumption of psilocybin-containing mushrooms. J. Psychoactive Drugs 53, 146\u2013148 (2021).","journal-title":"J. Psychoactive Drugs"},{"key":"39812_CR11","first-page":"1037","volume":"154","author":"FA Moreno","year":"1997","unstructured":"Moreno, F. A. & Delgado, P. L. Hallucinogen-induced relief of obsessions and compulsions. Am. J. Psychiatry 154, 1037\u20131038 (1997).","journal-title":"Am. J. Psychiatry"},{"key":"39812_CR12","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1080\/13284207.2022.2086793","volume":"27","author":"SG Moreton","year":"2023","unstructured":"Moreton, S. G., Burden-Hill, A. & Menzies, R. E. Reduced death anxiety and obsessive beliefs as mediators of the therapeutic effects of psychedelics on obsessive compulsive disorder symptomology. Clin. Psychol. 27, 58\u201373 (2023).","journal-title":"Clin. Psychol."},{"key":"39812_CR13","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.4088\/JCP.v67n1110","volume":"67","author":"FA Moreno","year":"2006","unstructured":"Moreno, F. A., Wiegand, C. B., Taitano, E. K. & Delgado, P. L. Safety, tolerability, and efficacy of psilocybin in 9 patients with obsessive-compulsive disorder. J. Clin. Psychiatry 67, 1735\u20131740 (2006).","journal-title":"J. Clin. Psychiatry"},{"key":"39812_CR14","doi-asserted-by":"crossref","first-page":"3047","DOI":"10.1007\/s00213-022-06221-6","volume":"239","author":"M Butler","year":"2022","unstructured":"Butler, M., Jelen, L. & Rucker, J. Expectancy in placebo-controlled trials of psychedelics: if so, so what?. Psychopharmacology 239, 3047\u20133055 (2022).","journal-title":"Psychopharmacology"},{"key":"39812_CR15","unstructured":"Arbel, O. Open Label, Phase 1 Study for Evaluating the Feasibility, Safety and Efficacy of Psychotherapy Assisted Psilocybin for Treatment of Severe OCD. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04882839 (2022)."},{"key":"39812_CR16","unstructured":"Kelmendi, B. Psilocybin Treatment in Obsessive-Compulsive Disorder: a Preliminary Efficacy Study and Exploratory Investigation of Neural Correlates. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03356483 (2021)."},{"key":"39812_CR17","unstructured":"Moreno, F. A. Psilocybin for Treatment of Obsessive Compulsive Disorder. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03300947 (2022)."},{"key":"39812_CR18","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.bbr.2015.08.018","volume":"296","author":"EJ Kyzar","year":"2016","unstructured":"Kyzar, E. J., Stewart, A. M. & Kalueff, A. V. Effects of LSD on grooming behavior in serotonin transporter heterozygous (Sert+\/\u2212) mice. Behav. Brain Res. 296, 47\u201352 (2016).","journal-title":"Behav. Brain Res."},{"key":"39812_CR19","doi-asserted-by":"crossref","first-page":"1866","DOI":"10.1271\/bbb.90095","volume":"73","author":"Y Matsushima","year":"2009","unstructured":"Matsushima, Y., Shirota, O., Kikura-Hanajiri, R., Goda, Y. & Eguchi, F. Effects of Psilocybe argentipes on marble-burying behavior in mice. Biosci. Biotechnol. Biochem. 73, 1866\u20131868 (2009).","journal-title":"Biosci. Biotechnol. Biochem."},{"key":"39812_CR20","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2019.107838","volume":"183","author":"AU Odland","year":"2021","unstructured":"Odland, A. U., Jessen, L., Kristensen, J. L., Fitzpatrick, C. M. & Andreasen, J. T. The 5-hydroxytryptamine 2A receptor agonists DOI and 25CN-NBOH decrease marble burying and reverse 8-OH-DPAT-induced deficit in spontaneous alternation. Neuropharmacology 183, 107838 (2021).","journal-title":"Neuropharmacology"},{"key":"39812_CR21","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1038\/nrn3530","volume":"14","author":"DJ Nutt","year":"2013","unstructured":"Nutt, D. J., King, L. A. & Nichols, D. E. Effects of Schedule I drug laws on neuroscience research and treatment innovation. Nat. Rev. Neurosci. 14, 577\u2013585 (2013).","journal-title":"Nat. Rev. Neurosci."},{"key":"39812_CR22","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1021\/acsptsci.1c00018","volume":"4","author":"G Agin-Liebes","year":"2021","unstructured":"Agin-Liebes, G. et al. Naturalistic use of mescaline is associated with self-reported psychiatric improvements and enduring positive life changes. ACS Pharmacol. Transl. Sci. 4, 543\u2013552 (2021).","journal-title":"ACS Pharmacol. Transl. Sci."},{"key":"39812_CR23","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1177\/0269881116662634","volume":"30","author":"TM Carbonaro","year":"2016","unstructured":"Carbonaro, T. M. et al. Survey study of challenging experiences after ingesting psilocybin mushrooms: Acute and enduring positive and negative consequences. J. Psychopharmacol. 30, 1268\u20131278 (2016).","journal-title":"J. Psychopharmacol."},{"key":"39812_CR24","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1177\/0269881119845793","volume":"33","author":"A Garcia-Romeu","year":"2019","unstructured":"Garcia-Romeu, A. et al. Cessation and reduction in alcohol consumption and misuse after psychedelic use. J. Psychopharmacol. 33, 1088\u20131101 (2019).","journal-title":"J. Psychopharmacol."},{"key":"39812_CR25","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1177\/0269881116684335","volume":"31","author":"MW Johnson","year":"2017","unstructured":"Johnson, M. W., Garcia-Romeu, A., Johnson, P. S. & Griffiths, R. R. An online survey of tobacco smoking cessation associated with naturalistic psychedelic use. J. Psychopharmacol. 31, 841\u2013850 (2017).","journal-title":"J. Psychopharmacol."},{"key":"39812_CR26","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1177\/0269881117691453","volume":"31","author":"VD Pisano","year":"2017","unstructured":"Pisano, V. D. et al. The association of psychedelic use and opioid use disorders among illicit users in the United States. J. Psychopharmacol. 31, 606\u2013613 (2017).","journal-title":"J. Psychopharmacol."},{"key":"39812_CR27","doi-asserted-by":"crossref","first-page":"205032451668332","DOI":"10.1177\/2050324516683325","volume":"3","author":"I Hartogsohn","year":"2017","unstructured":"Hartogsohn, I. Constructing drug effects: A history of set and setting. Drug Sci. Policy Law 3, 2050324516683325 (2017).","journal-title":"Drug Sci. Policy Law"},{"key":"39812_CR28","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbi.2019.103208","volume":"95","author":"PA Harris","year":"2019","unstructured":"Harris, P. A. et al. The REDCap consortium: Building an international community of software platform partners. J. Biomed. Inform. 95, 103208 (2019).","journal-title":"J. Biomed. Inform."},{"key":"39812_CR29","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1037\/1040-3590.14.4.485","volume":"14","author":"EB Foa","year":"2002","unstructured":"Foa, E. B. et al. The obsessive-compulsive inventory: Development and validation of a short version. Psychol. Assess. 14, 485\u2013496 (2002).","journal-title":"Psychol. Assess."},{"key":"39812_CR30","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/j.euroneuro.2013.12.006","volume":"24","author":"F Tyl\u0161","year":"2014","unstructured":"Tyl\u0161, F., P\u00e1len\u00ed\u010dek, T. & Hor\u00e1\u010dek, J. Psilocybin\u2013summary of knowledge and new perspectives. Eur. Neuropsychopharmacol. 24, 342\u2013356 (2014).","journal-title":"Eur. Neuropsychopharmacol."},{"key":"39812_CR31","doi-asserted-by":"crossref","unstructured":"Haijen, E. C. H. M. et al. Predicting responses to psychedelics: A prospective study. Front. Pharmacol. 9, (2018).","DOI":"10.3389\/fphar.2018.00897"},{"key":"39812_CR32","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1097\/HRP.0000000000000330","volume":"30","author":"ID Bandeira","year":"2022","unstructured":"Bandeira, I. D. et al. Ketamine in the treatment of obsessive-compulsive disorder: A systematic review. Harv. Rev. Psychiatry 30, 135\u2013145 (2022).","journal-title":"Harv. Rev. Psychiatry"},{"key":"39812_CR33","doi-asserted-by":"crossref","first-page":"S100","DOI":"10.1002\/jcph.1917","volume":"61","author":"K Waters","year":"2021","unstructured":"Waters, K. Pharmacologic similarities and differences among hallucinogens. J. Clin. Pharmacol. 61, S100\u2013S113 (2021).","journal-title":"J. Clin. Pharmacol."},{"key":"39812_CR34","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.bcp.2007.07.018","volume":"75","author":"WE Fantegrossi","year":"2008","unstructured":"Fantegrossi, W. E., Murnane, A. C. & Reissig, C. J. The behavioral pharmacology of hallucinogens. Biochem. Pharmacol. 75, 17\u201333 (2008).","journal-title":"Biochem. Pharmacol."},{"key":"39812_CR35","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1002\/dta.2292","volume":"10","author":"T Passie","year":"2018","unstructured":"Passie, T. & Benzenh\u00f6fer, U. MDA, MDMA, and other \u201cmescaline-like\u201d substances in the US military\u2019s search for a truth drug (1940s to 1960s). Drug Test. Anal. 10, 72\u201380 (2018).","journal-title":"Drug Test. Anal."},{"key":"39812_CR36","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.neuropharm.2011.01.017","volume":"61","author":"AL Halberstadt","year":"2011","unstructured":"Halberstadt, A. L. & Geyer, M. A. Multiple receptors contribute to the behavioral effects of indoleamine hallucinogens. Neuropharmacology 61, 364\u2013381 (2011).","journal-title":"Neuropharmacology"},{"key":"39812_CR37","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.pharmthera.2003.11.002","volume":"101","author":"DE Nichols","year":"2004","unstructured":"Nichols, D. E. Hallucinogens. Pharmacol. Ther. 101, 131\u2013181 (2004).","journal-title":"Pharmacol. Ther."},{"key":"39812_CR38","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0030800","volume":"7","author":"E Studerus","year":"2012","unstructured":"Studerus, E., Gamma, A., Kometer, M. & Vollenweider, F. X. Prediction of psilocybin response in healthy volunteers. PLoS ONE 7, e30800 (2012).","journal-title":"PLoS ONE"},{"key":"39812_CR39","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1056\/NEJMoa2032994","volume":"384","author":"R Carhart-Harris","year":"2021","unstructured":"Carhart-Harris, R. et al. Trial of Psilocybin versus Escitalopram for depression. N Engl J Med 384, 1402\u20131411 (2021).","journal-title":"N Engl J Med"},{"key":"39812_CR40","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1177\/0269881116675513","volume":"30","author":"RR Griffiths","year":"2016","unstructured":"Griffiths, R. R. et al. Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial. J. Psychopharmacol. 30, 1181\u20131197 (2016).","journal-title":"J. Psychopharmacol."},{"key":"39812_CR41","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2022.2096","author":"MP Bogenschutz","year":"2022","unstructured":"Bogenschutz, M. P. et al. Percentage of heavy drinking days following psilocybin-assisted psychotherapy vs placebo in the treatment of adult patients with alcohol use disorder: a randomized clinical trial. JAMA Psychiat. https:\/\/doi.org\/10.1001\/jamapsychiatry.2022.2096 (2022).","journal-title":"JAMA Psychiat."},{"key":"39812_CR42","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1007\/s40262-017-0513-9","volume":"56","author":"PC Dolder","year":"2017","unstructured":"Dolder, P. C. et al. Pharmacokinetics and pharmacodynamics of lysergic acid diethylamide in healthy subjects. Clin. Pharmacokinet. 56, 1219\u20131230 (2017).","journal-title":"Clin. Pharmacokinet."},{"key":"39812_CR43","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1080\/02791072.2014.963754","volume":"46","author":"JA Wilcox","year":"2014","unstructured":"Wilcox, J. A. Psilocybin and obsessive compulsive disorder. J. Psychoactive Drugs 46, 393\u2013395 (2014).","journal-title":"J. Psychoactive Drugs"},{"key":"39812_CR44","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1080\/02791072.1998.10399711","volume":"30","author":"PL Delgado","year":"1998","unstructured":"Delgado, P. L. & Moreno, F. A. Hallucinogens, serotonin and obsessive-compulsive disorder. J. Psychoactive Drugs 30, 359\u2013366 (1998).","journal-title":"J. Psychoactive Drugs"},{"key":"39812_CR45","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1177\/0269881116675513","volume":"30","author":"RR Griffiths","year":"2016","unstructured":"Griffiths, R. R. et al. Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial. J. Psychopharmacol. 30, 1181\u20131197 (2016).","journal-title":"J. Psychopharmacol."},{"key":"39812_CR46","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1007\/s00213-017-4771-x","volume":"235","author":"RL Carhart-Harris","year":"2018","unstructured":"Carhart-Harris, R. L. et al. Psilocybin with psychological support for treatment-resistant depression: six-month follow-up. Psychopharmacology 235, 399\u2013408 (2018).","journal-title":"Psychopharmacology"},{"key":"39812_CR47","doi-asserted-by":"crossref","first-page":"3170","DOI":"10.1016\/j.celrep.2018.05.022","volume":"23","author":"C Ly","year":"2018","unstructured":"Ly, C. et al. Psychedelics promote structural and functional neural plasticity. Cell Rep. 23, 3170\u20133182 (2018).","journal-title":"Cell Rep."},{"key":"39812_CR48","doi-asserted-by":"crossref","first-page":"2535","DOI":"10.1016\/j.neuron.2021.06.008","volume":"109","author":"L-X Shao","year":"2021","unstructured":"Shao, L.-X. et al. Psilocybin induces rapid and persistent growth of dendritic spines in frontal cortex in vivo. Neuron 109, 2535-2544.e4 (2021).","journal-title":"Neuron"},{"key":"39812_CR49","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1126\/science.adf0435","volume":"379","author":"MV Vargas","year":"2023","unstructured":"Vargas, M. V. et al. Psychedelics promote neuroplasticity through the activation of intracellular 5-HT2A receptors. Science 379, 700\u2013706 (2023).","journal-title":"Science"},{"key":"39812_CR50","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.comppsych.2017.04.002","volume":"76","author":"V Brakoulias","year":"2017","unstructured":"Brakoulias, V. et al. Comorbidity, age of onset and suicidality in obsessive-compulsive disorder (OCD): An international collaboration. Compr. Psychiatry 76, 79\u201386 (2017).","journal-title":"Compr. Psychiatry"},{"key":"39812_CR51","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/mp.2008.94","volume":"15","author":"AM Ruscio","year":"2010","unstructured":"Ruscio, A. M., Stein, D. J., Chiu, W. T. & Kessler, R. C. The epidemiology of obsessive-compulsive disorder in the National Comorbidity Survey Replication. Mol. Psychiatry 15, 53\u201363 (2010).","journal-title":"Mol. Psychiatry"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-39812-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-39812-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-39812-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,17]],"date-time":"2023-11-17T08:08:40Z","timestamp":1700208520000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-39812-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,17]]},"references-count":51,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["39812"],"URL":"https:\/\/doi.org\/10.1038\/s41598-023-39812-0","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,17]]},"assertion":[{"value":"13 March 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 July 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 August 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"AB, CP, AO, CD, EB, JFADS, KN, PS and MM declared no competing interests. MJ is a co-founding member of Eleusis (Psychedelic Society of French-speaking Switzerland) and SSMP (Swiss Society for Psychedelic Medicine) and board member of the Swiss Institute for Noetic Science (ISSNOE). VV and BW are president and member of the administration committee of the French psychedelic society, respectively (unpaid positions). LM is part of the Psychedelic medicine section of the AFPBN (French association for biological medicine and neuropsychopharmacology).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"13378"}}